Bleeding Risk Comparison: Clopidogrel vs Ticagrelor
Overall Bleeding Risk Profile
- The American Heart Association notes that clopidogrel has a better overall bleeding risk profile than ticagrelor, particularly for non-CABG major bleeding and gastrointestinal bleeding, though overall major bleeding rates are similar between the two agents 1, 2, 3
- The landmark PLATO trial demonstrated no significant difference in overall major bleeding between ticagrelor and clopidogrel (11.6% vs 11.2%; HR: 1.04; 95% CI: 0.95 to 1.13) 1
Non-CABG Major Bleeding
- Ticagrelor significantly increases non-CABG major bleeding compared to clopidogrel (4.5% vs 3.8%, P<0.03), representing a clinically meaningful 18% relative increase in bleeding risk 1, 2, 3
Special Population Considerations
- The European Society of Cardiology recommends that in patients with prior gastrointestinal bleeding, clopidogrel is strongly preferred over ticagrelor 4
- In patients with chronic kidney disease (CKD), ticagrelor demonstrates superior efficacy without increased bleeding risk compared to clopidogrel 5
- The American College of Cardiology notes that in PLATO patients with estimated GFR <60 mL/min, ticagrelor reduced cardiovascular endpoints (17.3% vs 22.0%; HR: 0.77; 95% CI: 0.65 to 0.90) with no differences in major bleeding, fatal bleeding, or non-CABG major bleeding 5
Clinical Decision Algorithm
- The American Heart Association suggests choosing clopidogrel when there is a history of gastrointestinal bleeding (strongest indication) 4
- The European Society of Cardiology recommends choosing ticagrelor when there is chronic kidney disease with GFR <60 mL/min (efficacy benefit outweighs bleeding risk) 5
- The American College of Cardiology notes that ticagrelor should be avoided in patients with prior stroke or TIA (prasugrel is contraindicated; clopidogrel preferred) 6, 2, 3
Critical Caveats
- The mortality benefit of ticagrelor (4.5% vs 5.9%; HR: 0.78) must be weighed against bleeding risk in individual patients 1
- Proton pump inhibitor co-administration is mandatory for all patients with GI bleeding history on either agent, representing a Class I recommendation that can partially mitigate the increased GI bleeding risk with ticagrelor 6, 7, 8